Towards greener pharmaceutical quality control: first green UV-based analytical strategies for assaying the newly-introduced candesartan/chlorthalidone mixture in their pharmaceutical and dissolution medium

Abstract

Emerging evidence suggests that antihypertensive therapies, particularly angiotensin II receptor blockers, play a crucial role in reinforcing clinical outcomes and hastening recovery in COVID-19 patients with hypertension. Thus, this study introduces the first UV scenarios for concurrent analysis of candesartan cilexetil (CDS) and chlorthalidone (CTL), which have superimposed UV spectra. The UV scenarios were the dual-wavelength (DUW) method and the Fourier deconvoluted (FOD) method. These scenarios were successfully implemented for the examination of CDS and CTL in their crude and commercial forms. In addition, this study provided a dissolution study of their formulation in accordance with the FDA's guidelines. The linear ranges were established to be (1.0–40.0) μg/mL for CDS and (5.0–60.0) μg/mL for CTL. The LOD values ranged between (0.23–0.24) μg/mL and (0.74–0.75) μg/mL for CDS and CTL, in order. Validation and confirmation of the proposed scenarios were performed according to ICH guidelines, yielding satisfactory results within acceptable limits. Statistical appraisal with the published platform revealed no significant differences. Aligned with green analytical chemistry principles, the proposed scenarios were appraised for their environmental impact and contrasted to the published platform using Eco-Scale and AGREEprep tools. The favorable results, coupled with the methods' sustainability, affordability, simplicity, and high sensitivity, support their use in routine QC testing.